Sarcomas and bone tumors pose a distinctive challenge in oncology imaging, necessitating standardized protocols for precise tumor response determination in clinical trials. Multiple imaging techniques are needed to address the heterogeneity of these tumors. Imaging Endpoints applies the leading and… Read More
Hematologic cancers, originating from lymphoid and myeloid cell lines, represent about 10% of newly diagnosed malignant tumors in the United States. Among these, Multiple Myeloma survival has improved over the last decade, with the emergence of cutting-edge therapies like CAR… Read More
To arrange a conversation with our proficient medical and scientific affairs experts and discover how we can help your clinical trials with tailored imaging solutions
The evolution of cancer treatment is experiencing the emergence of immune checkpoint blockade as a promising strategy with distinct response patterns and challenges. Medical imaging plays a pivotal role in evaluating responses to immunotherapy and monitoring immune-related adverse events, challenging… Read More
Overview: Imaging Endpoints (IE) has established a strong reputation for quality through a perfect inspection record and remarkable marketing authorization success rate and is expanding its quality leadership by integrating the new standards of ICH E6 (R3) into IE’s Quality… Read More
May 7, 2024 SCOTTSDALE, AZ – Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution EndpointsTM, focused on leveraging the Company’s strong leadership and financial position to acquire… Read More
On Tuesday, 23 April 2024, the U.S. FDA granted accelerated approval to Day One Biopharmaceuticals for tovorafenib, the first targeted therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). As explained in Day One’s press release, “pLGG is the… Read More
January 2024 – Imaging Endpoints (IE) is a global leader specializing in comprehensive imaging services for clinical trials. Our profound expertise includes analysis of CT, MRI, and PET/SPECT molecular imaging, particularly in the context of gynecologic malignancies, including cervical cancer.… Read More
September is a significant month for many reasons, but in the medical community, it stands out as Childhood Cancer Awareness Month. This month, we spotlight the pressing global health challenge of childhood cancer, which remains one of the leading causes… Read More
SCOTTSDALE, AZ — Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer. Dr Sharma, a radiologist with… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
